Abstract:BACKGROUND:The benefit of induction chemotherapy in locally advanced oral squamous cell carcinoma (OSCC) remains to be clearly defined. Induction chemotherapy is likely to be effective for biologically distinct subgroups of patients and biomarker development might lead to identification of the patients whose tumors are to respond to a particular treatment. Annexin A1 may serve as a biomarker for responsiveness to induction chemotherapy. The aim of this study was to investigate Annexin A1 expression in pre-treatment biopsies from a cohort of OSCC patients treated with surgery and post-operative radiotherapy or docetaxel, cisplatin and 5-fluorouracil (TPF) induction chemotherapy followed by surgery and post-operative radiotherapy. Furthermore we sought to assess the utility of Annexin A1 as a prognostic or predictive biomarker.METHODS:Immunohistochemical staining for Annexin A1 was performed in pre-treatment biopsies from 232 of 256 clinical stage III/IVA OSCC patients. Annexin A1 index was estimated as the proportion of tumor cells (low and high, <50% and ≥50% of stained cells, respectively) to Annexin A1 cellular membrane and cytoplasm staining.RESULTS:There was a significant correlation between Annexin A1 expression and pathologic differentiation grade (P=0.015) in OSCC patients. The proportion of patients with low Annexin A1 expression was significantly higher amongst those with moderate/poorly differentiated tumor (78/167) compared to those with well differentiated tumor (18/65). Multivariate Cox model analysis showed clinical stage (P=0.001) and Annexin A1 expression (P=0.038) as independent prognostic risk factors. Furthermore, a low Annexin A1 expression level was predictive of longer disease-free survival (P=0.036, HR=0.620) and locoregional recurrence-free survival (P=0.031, HR=0.607) compared to high Annexin A1 expression. Patients with moderate/poorly differentiated tumor and low Annexin A1 expression benefited from TPF induction chemotherapy as measured by distant metastasis-free survival (P=0.048, HR=0.373) as well as overall survival (P=0.078, HR=0.410).CONCLUSIONS:Annexin A1 can be used as a prognostic biomarker for OSCC. Patients with moderate/poorly differentiated OSCC and low Annexin A1 expression can benefit from the addition of TPF induction chemotherapy to surgery and post-operative radiotherapy. Annexin A1 expression can potentially be used as a predictive biomarker to select OSCC patients with moderate/poorly differentiated tumor who may benefit from TPF induction chemotherapy.

Clinical significance of Annexin A2 expression in oral squamous cell carcinoma and its influence on cell proliferation, migration and invasion

Increased expression of Annexin A2 in oral squamous cell carcinoma.

Expression and Significance of Annexin A2 in Patients with Gastric Adenocarcinoma and the Association with E-cadherin.

Decreased expression of Annexin A1 in oral squamous cell carcinoma

Annexin A5 is a novel prognostic biomarker in oral squamous cell carcinoma

Decreased expression of Annexin A1 correlates with pathologic differentiation grade in oral squamous cell carcinoma.

Annexin A1 Down-Regulation in Oral Squamous Cell Carcinoma Correlates to Pathological Differentiation Grade.

Association of annexin A2 with cancer development (Review).

Prognostic and Diagnostic Significance of Annexin A2 in Colorectal Cancer.

Overexpression of Angiopoietin 2 Promotes the Formation of Oral Squamous Cell Carcinoma by Increasing Epithelial–mesenchymal Transition-Induced Angiogenesis

Clinicopathological Value and Underlying Molecular Mechanism of Annexin A2 in 992 Cases of Thyroid Carcinoma

Overexpression of ANXA2 predicts adverse outcomes of patients with malignant tumors: a systematic review and meta-analysis

The Association of Annexin A2 with Malignant Tumor

Annexin A2 Enhances the Progression of Colorectal Cancer and Hepatocarcinoma via Cytoskeleton Structural Rearrangements

Angiopoietin-2 expression is correlated with angiogenesis and overall survival in oral squamous cell carcinoma

Targeting annexin A2 reduces tumorigenesis and therapeutic resistance of nasopharyngeal carcinoma

Silencing ANLN Hinders the Proliferation, Migration, Invasion, and Angiogenesis of Oral Squamous Cell Carcinoma

Annexin A2 (ANX A2): An emerging biomarker and potential therapeutic target for aggressive cancers

Association of serum annexin A1 with treatment response and prognosis in patients with esophageal squamous cell carcinoma

[Expression and Significance of Angiopoietin-1 and Angiopoietin-2 in Oral Squamous Cell Cacinoma].

Low Annexin A1 Expression Predicts Benefit from Induction Chemotherapy in Oral Cancer Patients with Moderate or Poor Pathologic Differentiation Grade